Gram-Negative Bacterial Infections

Subscribe to Selected New Research on Gram-Negative Bacterial Infections

230 relevant articles (22 outcomes, 16 trials/studies) found for this Disease

Description: Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.

Also Known As:

Infections, Gram-Negative Bacterial; Bacterial Infection, Gram-Negative; Bacterial Infections, Gram Negative; Gram Negative Bacterial Infections; Gram-Negative Bacterial Infection; Infection, Gram-Negative Bacterial; Infections, Gram Negative Bacterial; Bacterial Infections, Gram-Negative

Relationship Network

Disease Context: Research Results

Bacterial Infections and Mycoses

Bacterial Infections: 6393

Related Diseases

1.	Infection
2.	Kidney Failure (Renal Failure)
3.	Sepsis (Septicemia)
4.	Agranulocytosis (Granulocytopenia)
5.	Staphylococcal Infections

Experts

1.	Tam, Vincent H: 1 article (02/2008)
2.	Hou, JingGuo: 1 article (02/2008)
3.	Hou, Jingguo: 1 article (02/2008)
4.	Lim, Tze-Peng: 1 article (02/2008)
5.	Low, Jenny G H: 1 article (02/2008)
6.	Kwa, Andrea L H: 1 article (02/2008)
7.	Kurup, Asok: 1 article (02/2008)
8.	Prince, Randall A: 1 article (02/2008)
9.	Chen, H H: 1 article (10/2007)
10.	Chan, J: 1 article (10/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Gram-Negative Bacterial Infections:

1.	Anti-Bacterial Agents (Antibiotics)IBA 04/01/1995 - "The 2-pyridones are potent, orally available antibacterial agents with efficacy against gram-positive and gram-negative bacterial infections in mice." 04/01/2001 - "This resistance limits the arsenal of antibiotics that are effective in treating gram-negative bacterial infections" 05/01/2008 - "Raised LPS levels occur mainly in patients with Gram-negative bacterial infections who have been treated with bacteriocidal antibiotics" 01/01/2008 - "Treatment of Gram-negative bacterial infections is complicated by innate and acquired drug resistance resulting in a limited number of effective antibiotics" 08/15/2007 - "Aminoglycoside antibiotics are the most commonly used antibiotics worldwide in the treatment of Gram-negative bacterial infections" Order ALL the reference details at left...
2.	Ciprofloxacin (Cipro)FDA LinkGeneric 05/01/1990 - "This interaction resulted in significantly higher and more prolonged concentrations of ciprofloxacin in serum, which may be beneficial in the treatment of serious gram-negative bacterial infections, but it could also produce greater toxicity or result in more pronounced effects on oxidative drug metabolism of other medications." 08/01/2000 - "CONCLUSION: Ciprofloxacin prophylaxis eliminates gram-negative bacterial infection in bile and minimizes sludge formation and may have a potential benefit in delaying stent blockage." 01/01/1993 - "The incidence of documented Gram-negative bacterial infections was markedly reduced by ciprofloxacin prophylaxis; however, the number of Gram-positive infections may increase dramatically" 09/01/1996 - "Prophylactic ciprofloxacin and rifampin is a well-tolerated and highly effective combination that effectively decreases the risk of both gram-positive and gram-negative bacterial infection following HDC/ASCR" 04/01/1995 - "ABT-719 was equivalent in efficacy to ciprofloxacin for treatment of gram-negative bacterial infections caused by Pseudomonas aeruginosa or Escherichia coli" Order ALL the reference details at left...
3.	Gentamicins (Gentamicin)FDA LinkGeneric 03/01/2003 - "BACKGROUND: Once-daily dosing (ODD) of gentamicin is advocated as an effective and safe treatment of Gram-negative bacterial infections in adults" 02/01/1995 - "Fifty children aged 3 months--16 y with Gram-negative bacterial infections, were evaluated in this open randomized study; 26 received gentamicin 4.5 mg/kg/day, once daily, and 24 received the same daily dosage, in three divided doses" 07/01/2007 - "Gentamicin (GM) is an aminoglycoside antibiotic commonly used against life threatening gram negative bacterial infections, however, nephrotoxicity remains the major concern for its long term use" 09/01/2004 - "PURPOSE: Gentamicin is commonly prescribed for treatment of gram-negative bacterial infections" 06/01/2003 - "Gentamicin is an aminoglycosidic antibiotic widely used in the treatment of many gram-negative bacterial infections" Order ALL the reference details at left...
4.	Aztreonam FDA Link 02/08/1985 - "Multicenter trials were conducted to determine the safety and efficacy of aztreonam in the treatment of patients with gram-negative bacterial infections" 04/01/1992 - "A randomized double-blind clinical trial was done of aztreonam versus aminoglycoside therapy for the empiric treatment of seriously ill nonneutropenic patients suspected of aerobic gram-negative bacterial infection" 05/01/1991 - "On the basis of these data, aztreonam is considered an appropriate alternative agent for the treatment of serious gram-negative bacterial infections in neonates and children" 05/01/1991 - "The in vitro activity, pharmacokinetics, bactericidal activity, and tissue penetration of aztreonam suggest that it may play a role in therapy for serious gram-negative bacterial infections in children" 05/01/1989 - "Efficacy and safety of low dose aztreonam in the treatment of moderate to severe gram-negative bacterial infections." Order ALL the reference details at left...
5.	Tobramycin (Nebcin)FDA LinkGeneric 05/01/1978 - "Thirty-one patients with severe gram-negative bacterial infections were treated successfully with a combination of cefamandole nafate plus gentamicin or tobramycin" 01/01/1987 - "In an examination of the relationships among plasma aminoglycoside concentrations, the minimal inhibitory concentration (MIC) for the infecting organism, and therapeutic outcome, data were analyzed from 236 patients with gram-negative bacterial infections who were participants in four clinical trials of gentamicin, tobramycin, and amikacin" 05/01/1978 - "Efficacy and safety of cefamandole plus either gentamicin or tobramycin in therapy of severe gram-negative bacterial infections." 06/01/2007 - "Specifically, we compared the efficacy of Zymar (gatifloxacin 0.3%), Ciloxan (ciprofloxacin 0.3%), and fortified tobramycin (14 mg/mL) in the treatment of experimental Gram-negative bacterial infections of Serratia marcescens (SM) and Pseudomonas aeruginosa (PA) in the New Zealand White (NZW) rabbit keratitis model" Order ALL the reference details at left...
6.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/04/2008 - "Consistent with our findings in mice, dual blockade of TLR2 and TLR4 inhibited TNF-alpha release from human peripheral blood mononuclear cells upon Gram-negative bacterial infection/antibiotic therapy" 08/01/2004 - "These low responses of patients' blood to LPS or TNF-alpha support our finding that phagocytes are not fully activated when gram-negative bacterial infections occur." 09/01/1993 - "We assessed the effect of two factors associated with gram-negative bacterial infection, lipopolysaccharide (LPS) and TNF-alpha, on polymorphonuclear neutrophilic granulocytes (PMN) obtained from adult or newborns (umbilical cord blood)" 05/01/1993 - "We conclude that the magnitude and kinetics of TNF-alpha production and TNF-alpha-dependent immunophysiological responses are differentially regulated after lethal fungal vs. gram-negative bacterial infection" 06/01/2000 - "Recent studies have shown that mast cell-derived TNF-alpha plays a critical role in host defense against Gram negative bacterial infections by the recruitment of neutrophils to the sites of infection" Order ALL the reference details at left...
7.	Norfloxacin FDA Link 01/01/1988 - "We have previously demonstrated that the ability to suppress bacterial colonization of this site with oral norfloxacin prophylaxis (400 mg every 12 h) affects the incidence and distribution of aerobic gram-negative bacterial infections and the overall management of infectious complications in this patient population" 07/01/1989 - "Prophylactic administration of oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemias." 01/01/1988 - "We have now determined the broad impact of continuous, long-term use of oral norfloxacin on aerobic gram-negative bacterial infection and colonization, overall management of presumed and documented infections during marrow aplasia and emergence of clinically significant antibiotic resistant pathogens during intensive antileukemic chemotherapy" 01/01/1986 - "The efficacy of norfloxacin administered prophylactically throughout the course of intensive therapy and deep (less than 100 mm/3), prolonged (median 32 day) granulocytopenia against infections arising from the GI tract was demonstrated by its impact on the clinical manifestations of infection, microbiologically documented gram negative bacterial infections, overall antibiotic management, and GI colonization" 01/01/1987 - "Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia" Order ALL the reference details at left...
8.	enrofloxacinIBA 10/01/1990 - "Based on the concentrations achieved in these preliminary trials and the susceptibility patterns of gram-negative bacteria isolated from psittacine birds, drinking water medicated with enrofloxacin at 0.19-0.75 mg/ml might be effective for treating highly susceptible gram-negative bacterial infections in African grey parrots." Order ALL the reference details at left...
9.	Colistin (Coly-Mycin)FDA Link 09/01/2006 - "Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections." 06/01/1997 - "The Gram negative bacterial infections seemed to decrease with colimycin addition (33% versus 50%)" 02/01/1963 - "the treatment of gram-negative bacterial infection, especially Pseudomonas aeruginosa, the drug colistin has been known to be effective in some cases which were not helped by other antibiotics, including polymixin B" 12/01/2006 - "A retrospective cohort study evaluated the effectiveness and nephrotoxicity of intravenous colistin monotherapy vs. colistin-meropenem combination therapy for patients with multidrug-resistant Gram-negative bacterial infections" 12/01/2006 - "Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections." Order ALL the reference details at left...
10.	Ceftazidime (Fortum)FDA LinkGeneric 10/01/1997 - "During a 6-mo period (i.e., the before-period), our traditional practice of prescribing a third generation cephalosporin (ceftazidime) for the empiric treatment of suspected gram-negative bacterial infections was continued" 08/01/1989 - "It is concluded that pefloxacin is as effective as ceftazidime in moderate to severe gram-negative-bacterial infections, with similar trends toward development of resistance during therapy." 08/01/1989 - "Pefloxacin versus ceftazidime in the treatment of a variety of gram-negative-bacterial infections." 07/01/1987 - "aeruginosa and showed activity comparable to that of ceftazidime and cefotaxime against other gram-negative bacterial infections." 10/01/2000 - "INTERVENTIONS: During each time period, one antibiotic class was selected for the empirical treatment of Gram-negative bacterial infections as follows: time period 1 (baseline period) (1,323 patients), ceftazidime; time period 2 (1,243 patients), ciprofloxacin; and time period 3 (1,102 patients), cefepime" Order ALL the reference details at left...

Therapies and Procedures

1.	Intensive Care (Surgical Intensive Care) 11/01/1988 - "In a prospective randomized study to determine whether prevention of colonization of Gram-negative bacteria results in prevention of Gram-negative bacterial infections, 96 intensive care patients were randomly allocated into a control group and a study group" Order ALL the reference details at left...
2.	Transplantation (Transplant Recipients) 04/01/2006 - "Our study focused on immunization of recipient and donor mice with endotoxin prior to transplantation, in an attempt to reduce mortality caused by gram-negative bacterial infections posttransplantation" Order ALL the reference details at left...
3.	Drug Therapy (Chemotherapy) 10/01/2004 - "During myelosuppressive chemotherapy, Gram-negative bacterial infection with consequent exposure to lipopolysaccharide (LPS) is one of the most important causes of persistent fever" 01/01/1986 - "Aerobic gram negative bacterial infections occur commonly in patients with acute leukemia undergoing intensive chemotherapy-induced bone marrow aplasia, and often arise from the gastrointestinal (GI) tract" 05/01/2008 - "Important synergistic actions with conventional drug therapies have been observed with BCC including a reduction in LPS plasma levels in patients with Gram-negative bacterial infections treated with bactericidal antibiotics" 01/01/1988 - "We have now determined the broad impact of continuous, long-term use of oral norfloxacin on aerobic gram-negative bacterial infection and colonization, overall management of presumed and documented infections during marrow aplasia and emergence of clinically significant antibiotic resistant pathogens during intensive antileukemic chemotherapy" Order ALL the reference details at left...
4.	Stents 12/01/2000 - "CONCLUSIONS: In patients who had received antibiotic prophylaxis against gram-negative bacterial infection, anaerobic bacteria may play a role in initiating stent blockage." 08/01/2000 - "CONCLUSION: Ciprofloxacin prophylaxis eliminates gram-negative bacterial infection in bile and minimizes sludge formation and may have a potential benefit in delaying stent blockage." Order ALL the reference details at left...
5.	Immunotherapy 01/01/1995 - "Immunotherapy in gram-negative bacterial infections." 12/01/1992 - "Immunotherapy of severe gram-negative bacterial infections" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Gram-Negative Bacterial Infections

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 22 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface